Vesela Todorova Mitkova-Hristova

Prof. Dr. Vesela Todorova Mitkova-Hristova

Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria
orcid
Advancing vision through science, precision, and innovation.

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Life
Verified
Journal Article
Open access
PDF file
KKKrasimir Iliev Kraev
Krasimir Iliev Kraev
MGMariela Gencheva Geneva-Popova
Mariela Gencheva Geneva-Popova
BHBozhidar Krasimirov Hristov
Bozhidar Krasimirov Hristov
PUPetar Angelov Uchikov
Petar Angelov Uchikov
SPStanislava Popova-Belova
Stanislava Popova-Belova
Vesela Todorova Mitkova-HristovaVesela Todorova Mitkova-Hristova
Vesela Todorova Mitkova-Hristova
Febuxostat, initially developed as a xanthine oxidase inhibitor to address hyperuricemia in gout patients, has evolved into a versatile therapeutic agent with multifaceted applications. This review provides a comprehensive overview of febuxostat’s mechanism of action, its effectiveness in gout management, its cardiovascular safety profile, renal and hepatic effects, musculoskeletal applications, safety considerations, and emerging research prospects. Febuxostat’s primary mechanism involves selective inhibition of xanthine oxidase, resulting in reduced uric acid production. Its pharmacokinetics require personalized dosing strategies based on individual characteristics. In gout management, febuxostat offers a compelling alternative, effectively lowering uric acid levels, relieving symptoms, and supporting long-term control, especially for patients intolerant to allopurinol. Recent studies have demonstrated its cardiovascular safety, and it exhibits minimal hepatotoxicity, making it suitable for those with liver comorbidities. Febuxostat’s potential nephroprotective effects and kidney stone prevention properties are noteworthy, particularly for gout patients with renal concerns. Beyond gout, its anti-inflammatory properties hint at applications in musculoskeletal conditions and a broader spectrum of clinical contexts, including metabolic syndrome. Emerging research explores febuxostat’s roles in cardiovascular health, neurological disorders, rheumatoid arthritis, and cancer therapy, driven by its anti-inflammatory and antioxidative properties. Future directions include personalized medicine, combination therapies, mechanistic insights, and ongoing long-term safety monitoring, collectively illuminating the promising landscape of febuxostat’s multifaceted therapeutic potential.

22 November 2023 in Life
Verified
Journal Article
Open access
PDF file
KKKrasimir Iliev Kraev
Krasimir Iliev Kraev
MGMariela Gencheva Geneva-Popova
Mariela Gencheva Geneva-Popova
BHBozhidar Krasimirov Hristov
Bozhidar Krasimirov Hristov
PUPetar Angelov Uchikov
Petar Angelov Uchikov
SPStanislava Popova-Belova
Stanislava Popova-Belova
AIAtanas Slavchev Ivanov
Atanas Slavchev Ivanov
Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical scrutiny. This comprehensive literature review embarks on an exploration of the multifaceted landscape of JAK inhibitors, providing insights into their safety profiles across diverse immune-mediated diseases. The introduction highlights the transformative influence of JAK inhibitors in the treatment of immune-mediated diseases. Historically, the therapeutic arsenal for these conditions included corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics. The advent of JAK inhibitors has revolutionized this landscape, although concerns about their safety persist. This review strives to comprehensively evaluate their safety, amalgamating knowledge from multiple studies and trials. The subsequent sections delve into the safety of specific JAK inhibitors in the context of rheumatoid arthritis, inflammatory bowel diseases, and dermatologic conditions and their associations with venous thromboembolism. The evolving understanding of TE risk, particularly the intricate relationship between these agents and immune-mediated diseases, is meticulously unravelled. The concluding remarks underscore the dynamic nature of TE risk assessment with regard to immune-mediated diseases involving JAK inhibitors. It underscores that risk assessment is multifactorial, influenced not only by the choice of JAK inhibitor but also by the nuances of the underlying immune-mediated disease and the unique patient characteristics. This review offers a holistic perspective on TE risks associated with JAK inhibitors and contributes to the ongoing dialogue regarding their safety in the realm of immune-mediated diseases.

1 December 2011 in Folia Medica
Verified
Journal Article
Closed access
PDF file
Vesela Todorova Mitkova-HristovaVesela Todorova Mitkova-Hristova
Vesela Todorova Mitkova-Hristova
MKMarieta I. Konareva-Kostyaneva
Marieta I. Konareva-Kostyaneva
AIM: The aim of the present study was to measure macular thickness in healthy eyes and find whether it changes with age. MATERIAL AND METHODS: We examined 163 healthy eyes of 84 healthy volunteers. In order to measure their macular thickness the patients were examined using spectral-domain optical coherent tomography (SD-ОСТ - iVue, Optovue). They were allocated into 6 age groups. RESULTS: The mean central macular thickness (inner circle - fovea centralis) was 248.9 ± 17.9 μm (mean ± SD), and the mean total macular thickness (an area including 9 subfields as defined by ETDRS) was 286.2 ± 13.9 μm (mean ± SD). We found that it correlated negatively with age (r = - 0.18; p = 0.03; Pearson correlation). CONCLUSION: We found a statistically significant decrease of mean macular thickness as age increased.

1 September 2012 in Folia Medica
Verified
Journal Article
Open access
PDF file
Vesela Todorova Mitkova-HristovaVesela Todorova Mitkova-Hristova
Vesela Todorova Mitkova-Hristova
MKMarieta Iv. Konareva-Kostianeva
Marieta Iv. Konareva-Kostianeva
In the present study we have made a review of the relevant literature on pathogenesis and modern diagnostic methods for macular edema (ME) in uveitis. Macular edema is a typical non-specific complication of uveitis, one of the common causes of visual impairment. ME can be found in all types of uveitis. In 85% of cases of intermediate uveitis, the visual impairment is due to the development of cystoid macular edema. The macula is more rarely affected in panuveitis (35%), anterior (20-26%) and posterior (20%) uveitis. The etiological agent is of great importance for the course and treatment of inflammatory diseases. Among the imaging diagnostic methods that are capable of detecting macular edema with fluid accumulation in the retina (either diffuse or distributed in cysts) are the fl uorescein angiography (FA) and the optical coherence tomography (ОСТ). OCT allows a quantitative assessment of retinal thickening and how it changes throughout therapy. FA can be used to determine very precisely the site of a vascular leakage and assess how badly the vascular wall has been affected by the inflammatory process. CONCLUSION: Macular edema occurring during an inflammatory process is one of the causes for visual acuity loss in uveitis. OCT and FA are useful complementary imaging methods for investigation of structural changes in retinal architecture in uveitis patients.

17 June 2025 in Life
Verified
Journal Article
Open access
PDF file
YBYordanka M. Basheva-Kraeva
Yordanka M. Basheva-Kraeva
KKKrasimir Iliev Kraev
Krasimir Iliev Kraev
PUPetar Angelov Uchikov
Petar Angelov Uchikov
MKMaria Kraeva
Maria Kraeva
BHBozhidar Krasimirov Hristov
Bozhidar Krasimirov Hristov
VVVeselin A. Vassilev
Veselin A. Vassilev
Seronegative sicca syndrome encompasses patients who present with xerostomia and/or keratoconjunctivitis sicca but lack anti-SSA/SSB antibodies and do not fulfill current classification criteria for primary Sjögren’s syndrome (pSS). Despite symptom overlap with pSS, these individuals remain diagnostically and therapeutically unclassified. This review studies the clinical, immunological, and pathological spectrum of seronegative sicca, highlighting its heterogeneity and the limitations of antibody-centric diagnostic frameworks. Histopathologic findings in some seronegative patients—including focal lymphocytic sialadenitis—mirror those seen in pSS, suggesting underlying immune-mediated glandular damage. In others, nonspecific or normal biopsy findings suggest non-immune mechanisms. New evidence of immune activity, such as elevated cytokines (BAFF, IFN-α), and novel autoantibodies (SP-1, CA-VI), further supports the concept of subclinical autoimmunity in a subset of these patients. Clinically, they often face significant burden, including dryness, fatigue, and pain, yet remain excluded from most research cohorts, therapeutic trials, and clinical guidelines. Their management is often individualized, relying on symptomatic therapies rather than immunomodulatory agents. The lack of validated diagnostic criteria and prognostic markers compounds the uncertainty surrounding disease evolution, as some patients may later seroconvert or develop systemic features. To address these gaps, a paradigm shift is needed—one that embraces the spectrum of sicca syndromes, incorporates advanced immunophenotyping, and allows inclusion of seronegative patients in research and care algorithms.

30 May 2025 in Life
Verified
Journal Article
Open access
PDF file
Vesela Todorova Mitkova-HristovaVesela Todorova Mitkova-Hristova
Vesela Todorova Mitkova-Hristova
MAMarin Atanassov
Marin Atanassov
Background: Uveitis encompasses a broad group of diseases with infectious and non-infectious etiologies, potentially leading to permanent and irreversible visual impairment. This study aimed to determine whether the etiology and anatomical location of uveitis influence the course and laterality of the disease. Methods: This retrospective observational study included patients with uveitis treated at the University Eye Clinic of “St. George” University Hospital in Plovdiv, Bulgaria, between January 2011 and December 2023. All participants underwent a comprehensive eye examination and minimal laboratory screening, with additional tests and specialist consultations performed when necessary. Uveitis cases were categorized into anterior, intermediate, posterior, and panuveitis according to anatomical location; unilateral or bilateral according to laterality; and acute, chronic, or recurrent based on disease course. Results: The study included 606 patients aged between 3 and 87 years. The etiology and anatomical location of uveitis were significantly associated with the course and laterality of the disease (p < 0.001). Anterior and posterior uveitis were mostly unilateral, with a defined cause and characterized by acute or recurring progression. Intermediate uveitis was mostly idiopathic and chronic, while panuveitis had a more uniform distribution regarding disease progression. Among cases with a determined etiology, HLA-B27-associated uveitis was the most common (32.5%), characterized by sequential involvement of both eyes and a recurrent course. Viral and toxoplasmic uveitis were more frequently unilateral. Conclusions: Our findings indicate that the etiology and anatomical location of uveitis can serve as prognostic factors for contralateral eye involvement and the progression of the inflammatory process. We found that anterior and posterior uveitis were predominantly unilateral and typically presented with an acute or recurrent course, whereas intermediate uveitis and panuveitis were more commonly chronic. In men, uveitis more often had an acute onset, while in women, it tended to follow a chronic course.